QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Follow-Up Questions
Qiagen NV (QGEN)의 PER은 얼마입니까?
Qiagen NV의 PER은 118.3673입니다
Qiagen NV의 CEO는 누구입니까?
Mr. Thierry Bernard은 2020부터 회사에 합류한 Qiagen NV의 Chief Executive Officer입니다.
QGEN 주식의 가격 성능은 어떻습니까?
QGEN의 현재 가격은 $45.94이며, 전 거래일에 increased 0.01% 하였습니다.
Qiagen NV의 주요 사업 주제나 업종은 무엇입니까?
Qiagen NV은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
Qiagen NV의 시가총액은 얼마입니까?
Qiagen NV의 현재 시가총액은 $9.9B입니다
Qiagen NV는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 18명의 분석가가 Qiagen NV에 대한 분석 평가를 실시했으며, 이는 5명의 강력한 매수, 8명의 매수, 11명의 보유, 0명의 매도, 그리고 5명의 강력한 매도를 포함합니다